Elicio Therapeutics (ELTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ELTX Elicio Therapeutics

Watchlist

4.590
+0.330+7.75%

Close Nov 1 16:00 ET

49.46MMarket Cap-1217P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
GlobeNewswireOct 31 08:30 ET
JonesTrading Initiates Elicio Therapeutics(ELTX.US) With Buy Rating, Announces Target Price $9
Moomoo NewsOct 30 16:31 ET · Ratings
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Yahoo FinanceOct 24 12:00 ET
Express News | Elicio Therapeutics: Appoints Robert Connelly as Principal Financial Officer
ReutersOct 17 08:33 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
BenzingaOct 1 08:07 ET
Elicio Therapeutics Announces Three Upcoming Presentations Focused on Its Lymph Node Targeted, MKRAS-Specific Amphiphile Vaccines
GlobeNewswireSep 13 08:30 ET

Comments

Jaguar8

Oct 31 07:34

NEWS

$Elicio Therapeutics (ELTX.US)$
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Elicio Therapeutics (Nasdaq: ELTX) announced two upcoming presentations in November 2024. At the SITC 39th Annual Meeting (Nov 6-10), they will present updated T cell and Disease-Free Survival data from the AMPLIFY-7P Phase 1 trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumor...

Jaguar8

Sep 13 07:59

NEWS

$Elicio Therapeutics (ELTX.US)$
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
Elicio Therapeutics (Nasdaq: ELTX)announced three upcoming presentations focusing on its lymph node targeted, mKRAS-specific Amphiphile vaccines. The presentations will take place at:
1. AACR Special Conference (Sept 15-18, 2024, Boston): Dr. Eileen O'Reilly will present Phase I AMPLIFY-7P trial updates.
2. RAS-Targeted Drug Developm...

Jaguar8

Aug 12 15:17

NEWS

$Elicio Therapeutics (ELTX.US)$
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

Jaguar8

May 23 16:33

$Elicio Therapeutics (ELTX.US)$
NEWS
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics revealed preliminary data from their AMPLIFY-7P Phase 1a study of ELI-002 7P at the ASCO 2024 Annual Meeting. The cancer vaccine candidate, targeting mKRAS-driven solid tumors, showed promising results. ELI-002 7P was well tolerated and induced a significant (~100x...